Date: 2014-02-18
Type of information: Series A financing round
Company: SynAffix (The Netherlands)
Investors: Aravis (Switzerland), BioGeneration Ventures (the Netherlands), MS Ventures (Germany), BOM Capital (the Netherlands)
Amount: undisclosed
Funding type: series A financing round
Planned used: The funds will be used to advance SynAffix’ GlycoConnect™ technology for creating next-generation antibody-drug conjugates. This technology enables the enzymatic introduction of a specific tag on the glycan moiety of a protein, followed by the conjugation of functional groups (e.g. a toxic payload). A key feature of GlycoConnect™ is that the conjugation technology does not require prior engineering of the protein. It preserves the integrity of the protein but at the same time retains the ease of traditional conjugation methodologies. The general and versatile applicability of GlycoConnect™ to glycoproteins – including monoclonal antibodies – has the potential to be a powerful asset in the site-specific construction of stable and homogeneous ADCs, a promising novel class of targeted cancer therapeutics.
Others: * On February 18, 2014, SynAffix, a protein engineering company focusing on the creation of next-generation Antibody-Drug Conjugates (ADCs), has announced the completion of its Series A investment round. Financial details have not been disclosed.
Investors in the round are Aravis SA (Switzerland), BioGeneration Ventures (the Netherlands), MS Ventures, the corporate venture capital fund of Merck Serono and BOM Capital (the Netherlands). Edward van Wezel (BioGeneration Ventures), Simon Nebel (Aravis SA) and Hakan Goker (MS Ventures) will join the company’s Board of Directors.
“
Therapeutic area: Cancer - Oncology
